Trial Profile

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sufentanil (Primary)
Indications Postoperative pain
Focus Registrational; Therapeutic Use
Sponsors AcelRx Pharmaceuticals; Talphera

Most Recent Events

09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
17 May 2021 According to an AcelRx Pharmaceuticals media release, pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management were published in Journal of Pain Research.
25 Mar 2021 Results (n=283) of pooled analysis of the DSUVIA Phase 3 trials, published in an AcelRx Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com